Natural Product (NP) Details
| General Information of the NP (ID: NP5764) | |||||
|---|---|---|---|---|---|
| Name |
Licochalcone A
|
||||
| Synonyms |
licochalcone a; 58749-22-7; Licochalcone-A; UNII-JTV5467968; CHEMBL139702; JTV5467968; (E)-3-(4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one; Licochalcone-A, Synthetic; 3-Dimethylallyl-4,4'-dihydroxy-6-methoxychalcone; (E)-3-[4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one; (2E)-3-[4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one; 2-Propen-1-one,3-[5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hydroxyphenyl)-, (2E)-; LICOAGROCHACONE A; LicochalconeA; Licohalconel A; (E)-3-[5-(1,1-Dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hydroxyphenyl)-2-propen-1-one; SCHEMBL114042; DTXSID10904181; CHEBI:125689; CHEBI:174541; 3-(4-hydroxy-2-methoxy-5-(2-methylbut-3-en-2-yl)phenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one; BCP08941; EBD46703; EX-A1193; HY-N0372; ZINC3873123; BDBM50068270; HSCI1_000078; LMPK12120424; MFCD01417903; s7828; AKOS026673964; CCG-208030; CS-5603; Licochalcone A, >=96.0% (HPLC); (E)-3-[5-(1,1-dimethylallyl)-4-hydroxy-2-methoxy-phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one; 2-Propen-1-one, 3-(5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)-, (E)-; AS-74730; AB0021119; V2343; 749L227; Q-100677; Q1644097; BRD-K99667445-001-01-4; Chalcone base + 2O, 1MeO, 1Prenyl or Licochalcone A (Not validated); (E)-3-[5-(1,1-Dimethyl-allyl)-4-hydroxy-2-methoxy-phenyl]-1-(4-hydroxy-phenyl)-propenone; 3-[5-((E)-1,1-Dimethyl-allyl)-4-hydroxy-2-methoxy-phenyl]-1-(4-hydroxy-phenyl)-propenone; 2-Propen-1-one, 3-[5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hydroxyphenyl)- (E)-
Click to Show/Hide
|
||||
| Species Origin | Glycyrrhiza inflata ... | Click to Show/Hide | |||
| Glycyrrhiza inflata | |||||
| Disease | Obesity [ICD-11: 5B81] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-5.023
MDCK Permeability
-4.856
PAMPA
- - -
HIA
- - -
Distribution
VDss
0.271
PPB
97.7%
BBB
- - -
Metabolism
CYP1A2 inhibitor
+++
CYP1A2 substrate
- - -
CYP2C19 inhibitor
+++
CYP2C19 substrate
- - -
CYP2C9 inhibitor
-
CYP2C9 substrate
+
CYP2D6 inhibitor
- -
CYP2D6 substrate
++
CYP3A4 inhibitor
+++
CYP3A4 substrate
- - -
CYP2B6 inhibitor
+++
CYP2B6 substrate
- - -
CYP2C8 inhibitor
+++
HLM Stability
+++
Excretion
CLplasma
10.576
T1/2
1.088
Toxicity
DILI
-
Rat Oral Acute Toxicity
-
FDAMDD
++
Respiratory
++
Human Hepatotoxicity
-
Ototoxicity
- -
Drug-induced Nephrotoxicity
- -
Drug-induced Neurotoxicity
++
Hematotoxicity
- - -
Genotoxicity
+
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C21H22O4
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC(C)(C=C)C1=C(C=C(C(=C1)C=CC(=O)C2=CC=C(C=C2)O)OC)O
|
||||
| InChI |
1S/C21H22O4/c1-5-21(2,3)17-12-15(20(25-4)13-19(17)24)8-11-18(23)14-6-9-16(22)10-7-14/h5-13,22,24H,1H2,2-4H3/b11-8+
|
||||
| InChIKey |
KAZSKMJFUPEHHW-DHZHZOJOSA-N
|
||||
| CAS Number |
CAS 58749-22-7
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| 5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | IFI27 | Molecule Info | |||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SGC-7901 | CVCL_0520 | Human gastric cancer | Homo sapiens | ||
| MKN45 | CVCL_0434 | Gastric adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
LCA alone or in combination with 5-FU may have significant anticancer effects on gastric cancer cells. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | PTPN1 messenger RNA (PTPN1) | Molecule Info | [3] | |
| KEGG Pathway | Adherens junction | Click to Show/Hide | ||
| 2 | Insulin signaling pathway | |||
| NetPath Pathway | FSH Signaling Pathway | Click to Show/Hide | ||
| Panther Pathway | Cadherin signaling pathway | Click to Show/Hide | ||
| Pathway Interaction Database | Insulin Pathway | Click to Show/Hide | ||
| 2 | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||
| 3 | Signaling events mediated by PTP1B | |||
| 4 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
| 5 | Signaling events mediated by TCPTP | |||
| 6 | IGF1 pathway | |||
| 7 | EGF receptor (ErbB1) signaling pathway | |||
| 8 | Posttranslational regulation of adherens junction stability and dissassembly | |||
| 9 | PDGFR-beta signaling pathway | |||
| 10 | N-cadherin signaling events | |||
| Reactome | Integrin alphaIIb beta3 signaling | Click to Show/Hide | ||
| 2 | Regulation of IFNG signaling | |||
| 3 | Regulation of IFNA signaling | |||
| 4 | Growth hormone receptor signaling | |||
| WikiPathways | Insulin Signaling | Click to Show/Hide | ||
| 2 | Growth hormone receptor signaling | |||
| 3 | Leptin signaling pathway | |||
| 4 | Interferon gamma signaling | |||
| 5 | Interferon alpha/beta signaling | |||
| 6 | Integrin alphaIIb beta3 signaling | |||
